The 2014 ESC guidelines on the diagnosis and management of hypertrophic cardiomyopathy: What is new? [ESC-Leitlinie 2014 zur Diagnose und zum Management der hypertrophischen Kardiomyopathie: Was ist neu?]

被引:0
|
作者
Maisch B. [1 ]
Mahrholdt H. [2 ]
机构
[1] Emer. Direktor der Klinik für Innere Medizin – Kardiologie, Fachbereich Medizinder Philipps‐Universität Marburg, privat: Feldbergstr. 45, Marburg
[2] Zentrum für Innere Medizin, Abteilung für Kardiologie, Robert-Bosch-Krankenhaus, Stuttgart
关键词
Amyloidosis; Anderson-Fabry disease; Athlete’s heart syndrome; Genetic classification; Storage diseases;
D O I
10.1007/s00059-014-4177-z
中图分类号
学科分类号
摘要
The 2014 European Society of Cardiology (ESC) guidelines on the diagnosis and management of hypertrophic cardiomyopathy (HCM) comprise 133 recommendations with 506 references. In comparison to the last 10-year-old American College of Cardiology Foundation (ACCF)/ESC guidelines new data have been added, such as recent studies on genetics, updated recommendations for family and genetic screening, a special emphasis on red flags in clinical symptomatology and diagnostic features for the identification of non-obstructive variants of HCM, on multimodality non-invasive imaging by echocardiography and cardiac magnetic resonance imaging (MRI) and a HCM risk formula for the assessment of sudden cardiac death within 5 years. Nevertheless, it should not be forgotten that the majority of patients with HCM lead a normal life. This detailed update and the structured recommendations are an excellent summary of the current knowledge on HCM for the cardiomyopathy specialist and also for internists and general physicians. © 2014, Urban & Vogel.
引用
收藏
页码:919 / 930
页数:11
相关论文
共 27 条